Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

355

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

September 30, 2030

Conditions

Solid Tumor CancerLocally AdvancedMetastatic Solid TumorsUrothelial Cancer

Interventions

DRUG

AVZO-103

Specific dose in protocol specified schedule

DRUG

Combination Agent

Per label based on combination agent used

Trial Locations (1)

RECRUITING

Avenzo Therapeutics Recruiting Site, Austin